NCT00376636

Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension

A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-Week Study to Investigate the Safety and Efficacy of the Oral Renin Inhibitor SPP635 Once Daily in Patients With Mild to Moderate Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Speedel Pharma Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.

Detailed description

Renin-Angiotensin system blockade is a well established target for treatment of high blood pressure. Blocking the system at the initial step, however, is a rather new concept that could only be implemented very recently through the availability of novel, oral, renin inhibitors. This study investigates the safety and efficacy of a novel oral renin inhibitor, SPP635.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	SPP635 (drug)

Timeline

• Start date: 2006-10-01
• Completion: 2007-05-01
• First posted: 2006-09-15
• Last updated: 2007-10-30

Locations

1 site across 1 country: Germany